Moderna Announces Data to be Presented at 2024 ASCO Annual Meeting

Moderna, Inc. (NASDAQ: MRNA) revealed that three abstracts focusing on the investigational mRNA therapy mRNA-4157 (V940) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago, IL. This therapy is being co-developed with Merck (MSD outside the United States and Canada).

The studies include:

1. Abstract #TPS9616 examines pembrolizumab with V940 versus pembrolizumab with placebo for treating high-risk stage II-IV melanoma. Presented by Dr. Jeffrey S. Weber on June 1.

2. Abstract #TPS8116 details a Phase 3 study of V940 and pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Presented by Dr. Jay M. Lee on June 1.

3. Abstract #LBA9512 provides a 3-year update on mRNA-4157 in resected melanoma. Presented by Dr. Jeffrey S. Weber on June 3.

Moderna will host an investor webcast on June 3 from 6:15 to 7:15 PM CDT to discuss these findings. The webcast will be available on Moderna's website and archived for 30 days.